NCT05069610View on ClinicalTrials.gov

Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 21, 2022

Primary Completion Date

October 31, 2023

Study Completion Date

December 18, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

AD17002

A recombinant protein

BIOLOGICAL

Placebo (Formulation buffer)

Formulation buffer

Trial Locations (2)

104

Advagene Biopharma, Taipei

333423

Chang Gun Medical Foundation, Taoyuan District

All Listed Sponsors
lead

Advagene Biopharma Co. Ltd.

INDUSTRY